ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 10671

Title: Recent Insights into FXR in Non-alcoholic Fatty Liver Disease

Reviewer code: 00926880

Science editor: Yuan Qi

Date sent for review: 2014-04-13 17:43

Date reviewed: 2014-04-16 18:36

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[ ] Grade A: Priority Publishing	Google Search:	[Y] Accept
[Y] Grade B (Very good)	[Y] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ]Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[ ] Minor revision
		[ ] No records	[ ] Major revision

COMMENTS TO AUTHORS

(1) This is a review on FXR and non-alcoholic fatty liver disease. This is unfortunately not a systematic review and it thus potentially contains some biased views of the authors. (2) The references are not in a standard format, e.g. reference 1, pages 254-269; reference 5, pages 239-46. (3) There are occasional grammatical mistakes.

BAISHIDENG PUBLISHING GROUP INC

ESPS Peer-review Report
Name of Journal: World Journal of Gastroenterology
ESPS Manuscript NO: 10671
Title: Recent Insights into FXR in Non-alcoholic Fatty Liver Disease
Reviewer code: 00069855
Science editor: Yuan Qi
Date sent for review: 2014-04-13 17:43
Date reviewed: 2014-04-24 13:31

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[Y] Accept
[Y] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ]Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[ ] Minor revision
		[ ] No records	[ ] Major revision

COMMENTS TO AUTHORS

Dear Authors: Thank you for sending your manuscript titled as Recent Insights into FXR in Non-alcoholic Fatty Liver Disease to WJG for publishing.   Your review article discussed the role of Farnesoid X receptor (FXR) in bile acid, lipid and glucose metabolism as well as in inhibiting inflammation and NAFLD progression. Therefore, you pointed out the possible treatment with FXR activation for NAFLD.   The discussion is reasonable and comprehensive, the writing is fluent with no grammar concern, and the literature cited was very new.   However, a few things need to be improved: 1) Should use Farnesoid X Receptor instead of FXR in the title, because FXR is not a very popular used abbreviation to most of readers; 2) Add authors and their information to the manuscript;   3) Insert page number for the manuscript; 4) A few words and punctuations in the manuscript need to be corrected.   Best wishes,   Sincerely Yours, One of Peer Reviewer of WJG